Equities analysts forecast that XBiotech Inc (NASDAQ:XBIT) will post earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for XBiotech’s earnings. XBiotech posted earnings of ($0.16) per share in the same quarter last year, which would suggest a positive year over year growth rate of 6.3%. The business is expected to issue its next earnings results on Thursday, August 8th.
According to Zacks, analysts expect that XBiotech will report full-year earnings of ($0.61) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.85) per share. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow XBiotech.
XBiotech (NASDAQ:XBIT) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter.
A number of brokerages have weighed in on XBIT. Piper Jaffray Companies set a $120.00 target price on bluebird bio and gave the stock a “hold” rating in a research report on Friday, June 14th. BidaskClub downgraded XBiotech from a “buy” rating to a “hold” rating in a research note on Monday, April 15th.
NASDAQ:XBIT traded down $0.05 during mid-day trading on Monday, reaching $7.14. The company’s stock had a trading volume of 71,706 shares, compared to its average volume of 231,917. XBiotech has a 12-month low of $2.13 and a 12-month high of $11.74. The firm’s fifty day simple moving average is $7.44. The stock has a market capitalization of $257.83 million, a PE ratio of -12.10 and a beta of 0.49.
In other news, major shareholder Fondation Rennes purchased 1,200,000 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was acquired at an average cost of $8.25 per share, for a total transaction of $9,900,000.00. Following the purchase, the insider now directly owns 5,110,282 shares in the company, valued at approximately $42,159,826.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 33.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Birchview Capital LP bought a new stake in shares of XBiotech during the 1st quarter valued at about $110,000. Marshall Wace LLP bought a new stake in shares of XBiotech during the 1st quarter valued at about $682,000. Finally, Tibra Equities Europe Ltd bought a new stake in shares of XBiotech during the 1st quarter valued at about $750,000. Institutional investors and hedge funds own 7.05% of the company’s stock.
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Further Reading: How Important is Technical Analysis of Stocks
Get a free copy of the Zacks research report on XBiotech (XBIT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.